Telomerase peptide vaccination: A phase I/II study in patients with non-small cell lung cancer

Cancer Immunology, Immunotherapy

Volumn 55, Issue 12, 2006, Pages 1553-1564

  Brunsvig, Paal F ^a   Aamdal, Steinar ^a   Gjertsen, Marianne K ^a   Kvalheim, Gunnar ^a   Markowski Grimsrud, Carrie J ^a   Sve, Ingunn ^a   Dyrhaug, Marianne ^a   Trachsel, Sissel ^a   Møller, Mona ^b   Eriksen, Jon A ^b   Gaudernack, Gustav ^a,c  

^a UNIVERSITY OF OSLO   (Norway)

^b GemVax AS   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Clinical trial; hTERT vaccine; NSCLC; Promiscuous Th epitope

Indexed keywords

GLUTAMYLALANYLARGINYLPROLYLALANYLLEUCYLLEUCYLTHREONYLSERYLARGINYLLEUCYLARGINYLPHENYLALANYLISOLEUCYLPROLYLLYSINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GV 1001; HR 2822; ISOLEUCYLLEUCYLALANYLLYSYLPHENYLALANYLLEUCYLHISTIDYLTRYPTOPHANYLLEUCINE; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BONE MARROW; BONE MARROW TOXICITY; CANCER STAGING; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IN VITRO STUDY; INFLAMMATION; LUNG NON SMALL CELL CANCER; LYMPHOCYTE PROLIFERATION; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIODIAGNOSIS; TREATMENT OUTCOME; VACCINATION;

ADULT; AGED; BONE MARROW CELLS; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; IMMUNOTHERAPY, ACTIVE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PEPTIDES; TELOMERASE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33745638729     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-006-0145-7     Document Type: Article

References (33)

1. Shepherd F, Carney D (2000) In: Hansen H (ed) Treatment of NSCLC in Textbook of lung cancer. Martin Dunitz
2. Pfister D, Johnson D, Azzoli C, et al. (2004) American Society of clinical oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. JCO 22:330-353
3. Woo Ey, Yeh H, Chu S, et al. (2002) Cutting edge; regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 168:4272-4276
4. Hege K, Carbone D (2003) Lung cancer vaccines and gene therapy. Lung Cancer 41:S103-S113
5. Autexier C (1999) Telomerase as a possible target for anticancer therapy. Chem Biol 6:R299-R303
6. Fujita Y, Fujikane T, Fujiuchi, et al. (2003) The diagnostic and prognostic relevance of Human Telomerase reverse transcriptase mRNA expression detected in situ in patients with nonsmall cell lung carcinoma. Cancer 298:1008-1013
7. Vonderheide RH, Hahn WC, Schultze JL, et al. (1999) The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10:673-679
8. Minev B, Hipp J, Firat H, et al. (2000) Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci USA 97:4796-4801
9. Vonderheide RH, Anderson KS, Hahn WC, et al. (2001) Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clin Cancer Res 7:3343-3348
10. Arai J, Yasukawa M, Ohminami H, et al. (2001) Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes. Blood 97:2903-2907
11. Hernandez J, Garcia-Pons F, Lone YC, et al. (2002) Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells. Proc Natl Acad Sci USA 99:12275-12280
12. Scardino A, Gross DA, Alves P, et al. (2002) HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol 168:5900-5906
13. Gross DA, Graff-Dubois S, Opolon P, et al. (2004) High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest 113:425-433
14. Schroers R, Huang XF, Hammer J, et al. (2002) Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells. Cancer Res 62:2600-2605
15. Schroers R, Shen L, Rollins L, et al. (2003) Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin Cancer Res 9:4743-4755
16. Uchida N, Otsuka T, Shigematsu H, et al. (1999) Differential gene expression of human telomerase-associated protein hTERT and TEP1 in human hematopoietic cells. Leuk Res 23:1127-1132
17. Tahara H, Yasui W, Tahara E, et al. (1999) Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections. Oncogene 18:1561-1567
18. Gjertsen MK, Buanes T, Rossland AR, et al. (2001) Intradermal RAS peptide vaccination with granulocyte-macrophage colony-stimulation factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 92:441-450
19. Vonderheide RH, Domchek SM, Schultze JL, et al. (2004) Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res 10:828-839
20. Ostrand-Rosenberg S (2005) CD4+ lymphocytes: a critical component of antitumor immunity. Cancer Invest 23:413-419
21. Mountain C, Dresler C (1997) Regional lymph node classification for lung cancer staging. Chest 111:1718-1723
22. Gjertsen MK, Saeterdal I, Saeboe-Larssen S, Gaudernack G (2003) HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes. J Mol Med 81:43-50
23. Testa NG, Molineux G (1993) Haematopoiesis: A practical approach, Volume 1, and First Edition. Oxford University Press, Oxford
24. Sutherland HJ, Eaves CJ, et al. (1991) Differential regulation of primitive human hematopoietic cells in long-term cultures maintained on genetically engineered murine stromal cells. Blood 3:666-672
25. Pettengell R, Luft T, et al. (1994) Direct comparison by limiting dilution analysis of long-term culture initiating cells in human bone marrow, umbilical cord blood, and blood stem cells. Blood 11:3653-3859
26. Rusten LS, Jacobsen SE, et al. (1994) Functional differences between CD38- and DR-subfractions of CD34+ bone marrow cells. Blood 84:1473-1481
27. Danet-Desnoyers GA, Luongo JL, Bonnet DA, Domcheck SM, Vonderheide RH (2005) Telomerase vaccination has no detectable effect on SCID-repopulating and colony-forming activities in the bone marrow of cancer patients. Exp Hematol 33:1275-1280
28. Sorensen JB, Hansen HH, Hansen M, et al. (1988) Brain metastasis in adenocarcinoma of the lung; frequency, risk groups, and prognosis. J Clin Oncol 6:1479-1480
29. Cibotti R, Kanellopoulos JM, Cabaniols J-P, et al. (1992) Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants. Proc Nati Acad Sci USA 89:416-420
30. Gross DA, Graff-Dubois S, Opolon P, et al. (2004) High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest 113:425-433
31. Parkhurst M, Riley J, et al. (2004) Immunization of patients with hTERT: 540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing Telomerase. Clin Cancer Res 10:4688-4698
32. Abstr. # 3IN http://www.ex2.excerptamedica.com/ciw-04esmo/
33. Hirschowitz E, Foody T, Yanelli J, et al. (2004) Autologous dendritic cell vaccines for non-small cell lung cancer. JCO 22:2808-2815